{"id":"NCT04115488","sponsor":"Polpharma Biologics S.A.","briefTitle":"Efficacy and Safety of the Biosimilar Natalizumab PB006 in Comparison to Tysabri®","officialTitle":"Efficacy and Safety of the Biosimilar Natalizumab PB006 in Comparison to Tysabri® in Patients With Relapsing-Remitting Multiple Sclerosis (RRMS)","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2019-10-01","primaryCompletion":"2021-08-23","completion":"2022-02-07","firstPosted":"2019-10-04","resultsPosted":"2023-07-03","lastUpdate":"2023-07-03"},"enrollment":265,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"QUADRUPLE","primaryPurpose":"TREATMENT"},"conditions":["Relapsing-Remitting Multiple Sclerosis (RRMS)"],"interventions":[{"type":"BIOLOGICAL","name":"Intravenous (IV) infusions","otherNames":[]}],"arms":[{"label":"PB006","type":"EXPERIMENTAL"},{"label":"Tysabri","type":"ACTIVE_COMPARATOR"}],"summary":"This is a multi-center, randomized, parallel arm, double-blind study with a total duration of subjects' participation of 48 weeks. Approximately 260 participants with relapsing-remitting multiple sclerosis will be randomized to receive 12 doses of either PB006 or EU-licensed Natalizumab.","primaryOutcome":{"measure":"Cumulative Number of New Active Lesions Over 24 Weeks","timeFrame":"Scans performed at week 0 (baseline), week 8, 16, 20 and 24.","effectByArm":[{"arm":"PB006 (Per-Protocol)","deltaMin":1.4,"sd":3.73},{"arm":"Tysabri (Per-Protocol)","deltaMin":1.9,"sd":3.97},{"arm":"PB006 (Safety-Switch)","deltaMin":1.4,"sd":3.65},{"arm":"Tysabri Switched to PB006 at Week 24 (Safety-Switch)","deltaMin":2.1,"sd":3.78},{"arm":"Tysabri Continued at Week 24 (Safety-Switch)","deltaMin":1.9,"sd":4.09}],"pValues":[{"comp":"OG000 vs OG001","p":null}]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":3,"exclusionCount":7},"locations":{"siteCount":48,"countries":["Belarus","Croatia","Georgia","Moldova","Poland","Serbia","Ukraine"]},"refs":{"pmids":["36689214"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":3,"n":161},"commonTop":["Headache","Nasopharyngitis","COVID-19","Back pain","Oropharyngeal pain"]}}